Ovarian Cancer Immunotherapy: Overcoming Resistance, Predicting Response
Received Date: Aug 01, 2025 / Published Date: Aug 29, 2025
Abstract
Immune checkpoint inhibitors (ICIs) offer promise in ovarian cancer by reactivating anti-tumor immunity, but the immunosuppressive tumor microenvironment poses a challenge for durable efficacy. Combination strategies with chemotherapy, targeted therapies, and other immunotherapies are being investigated to overcome resistance. Biomarker identification is crucial for patient selection and response prediction. Addressing the immunosuppressive tumor microenvironment requires enhancing T-cell function, often through combinatorial approaches. Further research is needed to identify predictive biomarkers and optimize treatment strategies, including novel agents and personalized approaches, to improve outcomes in ovarian cancer
Citation: Sharma DR (2025) Ovarian Cancer Immunotherapy: Overcoming Resistance, Predicting Response. Current Trends Gynecol Oncol 10: 293.
Copyright: 漏 2025 Dr. Rajiv Sharma This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
Recommended Journals
Open Access Journals
Article Usage
- Total views: 248
- [From(publication date): 0-0 - Apr 06, 2026]
- Breakdown by view type
- HTML page views: 200
- PDF downloads: 48
